4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease

NCT01039701 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild to Moderate Alzheimer's Disease

Interventions

DRUG: AZD1446
DRUG: Placebo

Sponsor

AstraZeneca